Effect of continuous positive airway pressure therapy on circadian patterns of cardiac repolarization in patients with obstructive sleep apnoea: data from a randomized trial by Schlatzer, Christian et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Effect of continuous positive airway pressure therapy on circadian patterns
of cardiac repolarization in patients with obstructive sleep apnoea: data
from a randomized trial
Schlatzer, Christian; Bratton, Daniel J; Schwarz, Esther I; Gaisl, Thomas; Pepperell, Justin C T;
Stradling, John R; Kohler, Malcolm
Abstract: BACKGROUND: Regular airway clearance by chest physiotherapy and/or exercise is critical
to lung health in cystic fibrosis (CF). Combination of cycling exercise and chest physiotherapy using
the Flutter® device on sputum properties has not yet been investigated. METHODS: This prospective,
randomized crossover study compared a single bout of continuous cycling exercise at moderate intensity
(experiment A, control condition) vs a combination of interval cycling exercise plus Flutter® (experiment
B). Sputum properties (viscoelasticity, yield stress, solids content, spinnability, and ease of sputum ex-
pectoration), pulmonary diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO) were
assessed at rest, directly and 45 min post-exercise (recovery) at 2 consecutive visits. Primary outcome
was change in sputum viscoelasticity (G’, storage modulus; G”, loss modulus) over a broad frequency
range (0.1-100 rad.s- 1). RESULTS: 15 adults with CF (FEV1range 24-94% predicted) completed all
experiments. No consistent differences between experiments were observed for G’ and G” and other spu-
tum properties, except for ease of sputum expectoration during recovery favoring experiment A. DLNO,
DLCO, alveolar volume (VA) and pulmonary capillary blood volume (Vcap) increased during experiment
A, while DLCO and Vcap increased during experiment B (all P < 0.05). We found no differences in ab-
solute changes in pulmonary diffusing capacity and its components between experiments, except a higher
VA immediately post-exercise favoring Background Obstructive sleep apnoea (OSA) has been proposed
as an independent risk factor for sudden cardiac death (SCD). This study takes advantage of a previ-
ous randomized trial and seeks to evaluate circadian patterns of the QTc-interval, a marker of cardiac
repolarization and biomarker for SCD, in patients with OSA. We hypothesized that patients with OSA
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led to reductions in QTc, allowing reclassification into lower risk-associated values of QTc (<430 ms).
Conclusions In this exploratory study, CPAP treatment led to an overall reduction in the QTc-interval
compared with subtherapeutic CPAP. This reduction seems more pronounced during evening hours and
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Original Article
Effect of continuous positive airway pressure therapy on circadian 
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Background: Obstructive sleep apnoea (OSA) has been proposed as an independent risk factor for sudden 
cardiac death (SCD). This study takes advantage of a previous randomized trial and seeks to evaluate 
circadian patterns of the QTc-interval, a marker of cardiac repolarization and biomarker for SCD, in patients 
with OSA. We hypothesized that patients with OSA would exhibit longest QTc during the night-time and 
that continuous positive airway pressure (CPAP) therapy would reverse this.
Methods: One hundred eighteen patients diagnosed with moderate-to-severe OSA were randomized to 
receive therapeutic or subtherapeutic CPAP for 4 weeks. Of these, 84 had full 24 h-Holter monitoring data 
at baseline and follow-up. Weighted means of all QTc-intervals were analysed over 24 h, during four time-
periods (12 pm–6 am, 6 am–12 am, 12 am–6 pm, 6 pm–12 pm) as well as during each individual hour. A two-
sided P value <0.05 was considered to be of statistical significance.
Results: QTc-intervals at baseline [mean (SD) over 24 h: 407.8 ms (36.6)] were highest from 6 pm–12 pm 
[411.7 ms (42.0)] and shortest from 6 am–12 am [405.4 ms (39.5)]. Overall 24 h CPAP treatment effect on 
QTc was −11.3 ms [95% confidence interval (CI), −22.1 to −0.6; P=0.039] and was estimated to be greater 
from 6 pm–12 pm than from 12 pm–6 am (P=0.068). The CPAP treatment effect on QTc was driven by 
those patients in the highest QTc decile at baseline (all >430 ms). In these patients, CPAP led to reductions 
in QTc, allowing reclassification into lower risk-associated values of QTc (<430 ms).
Conclusions: In this exploratory study, CPAP treatment led to an overall reduction in the QTc-interval 
compared with subtherapeutic CPAP. This reduction seems more pronounced during evening hours and in 
patients with a QTc above 430 ms. 
Keywords: Obstructive sleep apnoea (OSA); sudden cardiac death (SCD); repolarization; QTc
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Introduction
Obstructive sleep apnoea (OSA) is a very common sleep-
related breathing disorder with estimated prevalence rates 
in the general population ranging from 2% to 25% in 
women and from 7% to 50% in men, when a cutoff of 
the apnoea-hypopnoea-index (AHI) ≥15 per h is applied, 
representing moderate-to-severe OSA (1,2). During sleep, 
repetitive interruption of ventilation, caused by partial or 
complete collapse of the pharynx, results in apnoea and 
arousals from sleep, thus leading to excessive daytime 
sleepiness, increased accident rates, elevated blood pressure 
and vascular dysfunction (3). OSA has been found to be 
independently associated with sudden cardiac death (SCD) 
in a large cohort study (4). It remains challenging to predict 
SCD, but one established marker for SCD risk stratification 
is the heart rate corrected QTc-interval, a marker of 
ventricular repolarization (5). It encompasses ventricular 
de- and repolarization, starting with the onset of the Q-wave 
and ending with the end of the T-wave. If prolonged, 
it is associated with torsade-de-pointes ventricular 
tachyarrhythmia, and SCD. Patients with OSA seem to be at 
greatest risk for SCD during sleeping hours, as opposed to 
patients without OSA (and the general population), in whom 
SCD is least likely to occur during that time period (6). 
This observation could in part be due to particularly long 
QTc-intervals during the night in OSA patients and is 
possibly reversible through continuous positive airway 
pressure (CPAP) therapy.
We have previously shown a clinically significant 
prolongation of the QTc-interval after a 2-week withdrawal 
of CPAP therapy in patients with OSA (7). A limitation of 
our previous study was that the QTc data had been derived 
from a standard resting 12-lead-electrocardiogram (ECG), 
thus not allowing a detailed analysis of day/night patterns 
of repolarization. Therefore, in the present study we sought 
to evaluate the effects of CPAP therapy on QTc-duration by 
an analysis of 24-h-Holter-ECG data collected in a previous 
RCT (8). 
We hypothesized that QTc in moderate-to-severe OSA 
patients at baseline would be highest during sleeping hours 
not only because this is found in the general population 
(9,10) but also because OSA may further lengthen it. If this 
is the case, CPAP would be expected to partially reverse 
this. 
Methods
Study design
Patients with possible OSA were referred to the Sleep and 
Respiratory Trials Unit, Oxford Centre for Respiratory 
Medicine, Oxford, UK and assessed for eligibility for a 
parallel, randomized, double-blind trial. The trial from 
which the data were drawn was previously published in 
2002 (8) and was approved by the central Oxford research 
ethics committee (Oxford, UK; COREC No. 96.127).
Study participants
Male patients aged between 30 and 75 years with excessive 
subjective daytime sleepiness [Epworth sleepiness scale 
(ESS) >9] (11) and proven OSA with >10 dips/h of >4% 
oxygen desaturation (ODI >10) were eligible for the trial. 
We did not include patients who preferred alternative 
treatments such as weight loss or tonsillectomy, or if they 
required urgent CPAP treatment due to respiratory failure 
or sleepiness-related vocational problems. Cardiovascular 
disease was not an exclusion criterion. All participants gave 
written informed consent.
Sleep study
A one-night in-hospital polygraphic (PG) sleep study was 
performed to diagnose OSA. The sleep study results were 
scored automatically, and subsequently manually reviewed 
for accuracy. An ODI of 10/h due to obstructive apnoeas 
was used as a cutoff, above which OSA was diagnosed.
Electrocardiography
Twenty-four-h-Holter electrocardiography was applied 
during the hospital assessments in the early afternoon. A 
commercially available (Cardioscan DL700; Breamar Inc., 
Bramwell, MN, USA) 3-channel-Holter recorder was 
used. The devices were then worn for the following 24 h 
during normal daily activities. Data were analysed using the 
Century 3000 system (UK Medical, Sheffield, UK). The 
QT-interval was defined as the time-interval from the onset 
of the QRS complex to the cutting point of the tangent to 
the downward slope of the T wave and the isoelectric line. 
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The QT-interval was then corrected for heart rate using 
Bazett’s formula (12).
CPAP therapy and randomization
After the first 24 h-ECG monitoring at baseline, 
participants were randomly assigned to either receive 
therapeutic or subtherapeutic CPAP by a series of presealed 
and numbered opaque envelopes and attended for a 
second in-hospital sleep study. A specialized nurse assigned 
participants to treatment groups and did not take part in the 
outcome analysis. The outcome assessors were not aware of 
the allocation of patients and were not involved in the set-
up and maintenance of CPAP devices. Sullivan Autoset-T 
autoadjusting (ResMed, Abingdon, UK) CPAP machines 
were used in both groups. Subtherapeutic CPAP, at too 
low a pressure to splint open the pharynx, was obtained by 
setting the CPAP machine to its lowest pressure, connecting 
a flow restrictor to the main tubing, and creating six extra 4 
mm holes in the collar of the main tubing at the end of the 
mask, to further drop the pressure (to <1 cmH2O) and thus 
prevent rebreathing of carbon dioxide. Further details are 
available in the prior publication (8). 
Outcomes
The primary endpoint of interest in this analysis was the 
CPAP treatment effect on the overall 24 h-QTc-interval. 
Secondary endpoints were baseline QTc-intervals and the 
CPAP treatment effect on QTc during four time periods 
(night from 12 pm–6 am, morning from 6 am–12 am, 
afternoon from 12 am–6 pm and evening from 6 pm–12 pm) 
and during each individual hour. 
Data analysis
Continuous variables were summarized as mean (SD). For 
each patient the mean QTc-interval in each time period 
of interest was calculated using a weighted mean with 
weights defined as the number of beats recorded in each 
hour. Mean QTc-intervals at baseline were summarized in 
the time periods defined above and compared using multi-
level mixed-effects regression adjusting for time period and 
including a patient-specific random intercept. 
Mean 24 h-intervals were compared between treatment 
groups using multiple linear regression. In the time periods 
defined above, outcomes were compared between treatment 
groups using multi-level mixed-effects regression including 
a treatment x time-period interaction and a patient-specific 
random intercept. Global tests for interaction were used 
to determine whether the effect of CPAP varied between 
each time-interval. All analyses were adjusted for the 
corresponding interval measured over 24 h at baseline and 
residuals were investigated for possible outliers.
The interaction between baseline mean 24 h QTc, ODI 
and CPAP usage with treatment effect on mean 24 h QTc 
was assessed using fractional polynomials, as described by 
Royston and Sauerbrei (13). The results of the modelling 
procedure were checked by estimating the treatment effect 
of CPAP at each decile of baseline mean 24 h-QTc. A 
two-sided P value <0.05 was considered to be of statistical 
significance.
Results
Trial profile and patient characteristics
Figure 1 shows the trial profile. Of the 339 eligible 
participants initially approached, 155 did not consent. 
Another 25 participants chose an alternative treatment, 
11 needed urgent CPAP treatment, 11 did not attend 
the first study day and 19 had inadequate baseline blood 
pressure, which was an exclusion criterion for the previously 
published trial (8). The remaining 118 participants were 
randomized to either receive therapeutic or subtherapeutic 
CPAP. In the therapeutic CPAP group, 2 patients 
discontinued CPAP, 4 did not attend for follow-up and 11 
had no, or inadequate (artifacts), ECG data at follow-up. In 
the subtherapeutic CPAP group, 2 discontinued CPAP, 6 
did not attend for follow-up and 13 had no, or inadequate 
(artifacts), ECG data at follow-up. Thus data from 84 
participants were available for analysis. Table 1 shows 
baseline characteristics of these participants, which were 
similar between treatment groups. There was no evidence 
of any significant difference in treatment effects of CPAP 
on OSA severity, subjective and objective sleepiness in our 
subset of patients when compared to the original trial (8). 
Baseline analysis
In both groups combined, mean QTc over 24 h was 
407.8 ms (36.6). Mean baseline QTc-intervals during four 
time periods are shown in Table 2 and during each individual 
hour in Figure 2. There was evidence of a difference in 
mean QTc between the four time periods (global test for 
difference P=0.005) with QTc-interval being longest during 
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Figure 1 Study flow.
339 eligible patients
59 therapeutic CPAP
2 discontinued CPAP
4 did not attend at follow-up
11 had no ECG at follow-up
59 subtherapeutic CPAP
2 discontinued CPAP
6 did not attend at follow-up
13 had no ECG at follow-up
41 full ECG data available
221 were ineligible:
155 did not give informed 
consent
25 chose alternative treatment
11 needed urgent treatment
11 did not attend
19 had inadequate baseline 
blood pressure (exclusion 
criterion for original trial)
43 full ECG data available
Allocation
Follow-Up
Analysis
Enrollment
118 patients randomized
Table 1 Baseline characteristics
Variables Therapeutic CPAP (N=43) Subtherapeutic CPAP (N=41)
Age (years) 49.3 (9.2) 49.3 (10.4)
BMI (kg/m2) 35.5 (7.2) 34.3 (5.0)
ODI (dips/h) 39.5 (22.9) 43.9 (22.6)
Smoking status
Current 9 [21] 8 [20]
Ex 19 [44] 22 [54]
Never 15 [35] 11 [27]
Arterial hypertension 11 [26] 10 [24]
Diabetes mellitus 0 1 [2]
Coronary heart disease 4 [9] 0
Congestive heart failure 1 [2] 0
Cerebrovascular disease 1 [2] 1 [2]
Beta blocker usage 5 [12] 1 [2]
Antiarrhythmic medication 0 0
Antihypertensive medication 13 [30] 8 [20]
24 h ECG measurements
Mean QTc, ms 409.0 (35.9) 406.6 (37.7)
Mean QT, ms 356.3 (41.1) 352.0 (37.1)
Min. QT, ms 238.0 (34.9) 233.5 (30.4)
Max. QT, ms 444.7 (53.2) 447.2 (45.6)
Heart rate, bpm 80.7 (11.7) 81.8 (11.3)
Data are presented as means (SD) or n (%) as appropriate. BMI, body mass index; ECG, electrocardiogram; ODI, oxygen desaturation  
index; QT, time interval of cardiac repolarization in ms; QTc, time interval of cardiac repolarization in ms, corrected for heart rate.
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evening hours with a mean of 411.7 ms (42.0). There was 
no correlation between baseline QTc and baseline severity 
of OSA (ODI) as a function of the 24 h period.
Effect of CPAP on cardiac repolarization
CPAP treatment effects on QTc are shown in Table 3. 
Therapeutic CPAP reduced mean QTc over 24 h by 
−11.3 ms [95% confidence interval (CI), −22.1 to −0.6; 
P=0.039] when compared with subtherapeutic CPAP. CPAP 
seemed to reduce QTc more during evening hours than 
during the rest of the day, although the test for treatment-
Figure 2 Baseline QTc-intervals in each individual hour in both groups. P value (H0: no change over time) <0.001. QTc, time interval of 
cardiac repolarization in ms, corrected for heart rate.
Table 2 Circadian effects on baseline QTc-intervals in both groups 
combined
Time period Mean QTc, ms Global test for difference
12 pm–6 am 405.5 (38.4)
P=0.005
6 am–12 am 405.4 (39.5)
12 am–6 pm 407.5 (39.6)
6 pm–12 pm 411.7 (42.0)
Total 24 h 407.8 (36.6) –
Data are presented as means (SD). QTc, time interval of cardiac 
repolarization in ms, corrected for heart rate.
Table 3 Effect of CPAP on mean 24 h QTc, and during the four time-periods
Time period
Therapeutic CPAP Subtherapeutic CPAP
Treatment effect (95% CI) P value
Baseline QTc, ms Follow-up QTc, ms Baseline QTc, ms Follow-up QTc, ms
Total 24 h 409.0 (35.9) 396.0 (16.2) 406.6 (37.7) 406.3 (38.5) −11.3 (−22.1 to −0.6) 0.039
12 pm–6 am* 406.9 (33.7) 393.7 (19.1) 403.9 (43.1) 403.4 (41.4) −11.1 (22.0 to −0.3) 0.044
6 am–12 am* 404.7 (40.0) 397.4 (18.4) 406.1 (39.4) 403.9 (31.1) −6.5 (−17.4 to 4.5) 0.25
12 am–6 pm* 410.9 (41.4) 395.4 (16.5) 404.0 (37.7) 404.1 (39.1) −9.7 (−20.5 to 1.1) 0.078
6 pm–12 pm* 415.8 (44.8) 396.4 (17.7) 407.2 (38.8) 410.9 (41.2) −15.5 (−26.3 to −4.6) 0.005
Data are presented as mean (SD) or mean (95% CI). *, test for treatment-time interaction: P=0.068. QTc, time interval of cardiac  
repolarization in ms, corrected for heart rate.
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time interaction did not quite reach statistical significance 
(P=0.068). Figure 3 shows the CPAP treatment effect on 
QTc in each individual hour. The CPAP treatment effect 
on QTc seemed to be mainly driven by 8 patients in the 
highest QTc decile at baseline (Figure 4) all of whom had a 
mean baseline 24 h-QTc >430 ms. By contrast, there was no 
treatment effect in the remaining participants.
Mean 24 h heart rate decreased by −2.4 beats per minute 
(95% CI, −5.5 to 0.6) through use of therapeutic CPAP, 
when compared with subtherapeutic CPAP, however in 
this subset of the original trial entrants the reduction was 
not quite statistically significant (P=0.12; Table 4). No 
interaction of baseline severity of OSA (ODI) and CPAP-
compliance on CPAP treatment effect on 24 h-QTc was 
found.
Discussion
The principle findings of this randomized controlled trial 
are that in patients with moderate-to-severe OSA, treatment 
with CPAP resulted in significant reductions of the QTc-
interval in patients with a high baseline QTc >430 ms, while 
no effect of CPAP was observed in patients with shorter 
QTc-intervals. 
Our group previously showed that withdrawal of an 
established CPAP treatment in moderate-to-severe OSA 
was associated with considerable prolongations of the QTc-
and T-peak-to-Tend (TpTe)-intervals (mean difference 21.4 
and 14.4 ms, respectively) (7). The current study sought 
to further investigate CPAP treatment effects on circadian 
patterns of cardiac repolarization. Contrary to our prior 
hypothesis, baseline QTc in patients with moderate-to-
severe OSA was longest during the evening hours rather 
than during sleeping hours. This may be because in patients 
with OSA the sleep period is heavily disrupted and thus 
interferes with the QTc prolongation with sleep observed 
Figure 3 Effect of CPAP on mean QTc in each individual hour. P value for treatment-time interaction: P=0.22. QTc, time interval of cardiac 
repolarization in ms, corrected for heart rate.
Figure 4 Interaction between (A) the effect of CPAP treatment on 
mean 24 h QTc and (B) the mean QTc at baseline. Note that points 
represent treatment effect estimates in deciles of patients—rather 
than single individuals—of baseline mean 24 h QTc. QTc, time 
interval of cardiac repolarization in ms, corrected for heart rate.
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in normal subjects (9,10). In addition, the treatment effect 
of CPAP on QTc also seemed to be greatest during the 
evening hours and not during sleeping hours. This may 
be because this was the period with the longest QTc at 
baseline and thus a larger effect size would be expected 
similar to the phenomenon seen in the 8 patients with the 
highest baseline QTc. However, it is unclear why a normal 
pattern of lengthening of QTc during sleep was not fully re-
established. The observed differences in baseline QTc could 
in part also be due to differences in heart rate at baseline, as 
both were highest during evening hours. A similar influence 
of heart rate on the effect of CPAP on QTc seems less likely 
as CPAP ‘normalized’ QTc during all time periods, which 
was not the case with heart rate, where circadian differences 
largely remained unchanged (see Table 4).
An interesting aspect of our analysis can be seen when 
comparing QTc-intervals and corresponding standard 
deviations (SD) in the two groups at follow-up (see Table 3). 
In the therapeutic CPAP group, irrespective of baseline 
QTc during all four time periods, inter-individual QTc 
variation at follow-up was reduced to a rather homogenous 
low level; in contrast to the subtherapeutic CPAP group, 
the SD of the mean QTc in the CPAP group is more than 
halved due to the QTc being ‘normalized’ in the patients 
with highest QTc at baseline (Figure 4). One could argue 
from this finding that CPAP might be able to normalize 
the QTc-interval, when a certain degree of abnormal 
prolongation was present before treatment. This argument 
is reinforced by the observation that the CPAP treatment 
effect was mainly driven by the 8 patients in the highest 
decile of baseline QTc (all >430 ms). The greatest CPAP 
treatment effect on QTc was observed in our previous 
CPAP withdrawal trial (7), in which patients had higher 
mean QTc-intervals at baseline when compared with the 
current trial (419 vs. 408 ms).
Biological plausibility 
The main direct pathophysiological consequences of 
OSA are intermittent hypoxia, arousals from sleep and 
intrathoracic pressure swings, all contributing to augmented 
sympathetic activity (3). Severe OSA has been shown to 
be associated with decreased baroreflex sensitivity (BRS), a 
marker of cardiac vagal responsiveness and treatment with 
CPAP in moderate-to-severe OSA increased daytime BRS 
by 24% after 4 weeks (14). This improvement is comparable 
with the effect of several months of endurance training in 
patients with mild hypertension (15). In the study by Kohler 
et al. (14) urine normetanephrine excretion decreased by 
26% with CPAP treatment. These findings all suggest 
that CPAP therapy in moderate-to-severe OSA patients 
decreases sympathetic overstimulation and improves 
sympathico-vagal imbalances. 
We have previously shown, in a model simulating 
OSA in 44 patients with paroxysmal atrial fibrillation, a 
mean QTc prolongation at the end of a 20 s simulated 
obstructive apnoea of 17.3 ms (95% CI, 10.7 to 23.9 ms, 
P=0.001) when compared with normal breathing (16). 
The timing and magnitude of the QTc-prolongation was 
strongly correlated with heart rate increases in the latter 
study suggesting the importance of sympathetic activation. 
A rise of over 200% in sympathetic activity was also found 
by Somers et al. (17) at the end of 20 seconds simulated 
apnoea. Although these conclusions derive from indirect 
observations of cardiac autonomic nerve activity, they 
imply pathophysiological OSA consequences that could 
lead to a prolongation of the QTc-interval and the reversal 
through use of CPAP therapy. 
Table 4 Effect of CPAP on heart rate
Time period
Therapeutic CPAP Subtherapeutic CPAP
Treatment effect 
(95% CI)
P valueBaseline heart rate 
(bpm)
Follow-up heart rate 
(bpm)
Baseline heart rate 
(bpm)
Follow-up heart rate 
(bpm)
Total 24 h 80.7 (11.7) 80.2 (12.0) 81.8 (11.3) 83.5 (10.4) −2.4 (−5.5 to 0.6) 0.12
12 pm–6 am* 73.8 (12.7) 71.5 (12.1) 71.1 (10.7) 73.2 (10.5) −0.3 (−4.0 to 3.4) 0.88
6 am–12 am* 81.8 (12.2) 80.1 (13.4) 82.7 (13.1) 84.7 (13.9) −3.0 (−6.8 to 0.8) 0.12
12 am–6 pm* 83.6 (13.1) 82.3 (11.9) 86.9 (13.3) 84.8 (12.4) −1.6 (−5.3 to 2.0) 0.38
6 pm–12 pm* 87.2 (14.1) 85.0 (12.0) 82.9 (12.8) 87.7 (11.6) −1.6 (−5.3 to 2.1) 0.39
Data are presented as mean (SD) or mean (95% CI). *, test for treatment-time interaction: P=0.65.
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Impact of QTc on SCD?
While the effect of QTc-prolongation on the incidence 
of SCD in the general population seems to be small and 
difficult to detect reliably, the effect in patients with 
underlying cardiovascular disease is likely to be greater, as 
pointed out by Montanez et al. (18). In a case-control study 
by Panikkath et al. (19), QTc was the only ECG-derived 
interval independently associated with SCD in patients with 
left ventricular hypertrophy. The patients in our study had 
a relatively high cardiovascular risk profile, typical for the 
majority of patients diagnosed with moderate-to-severe 
OSA. In the Rotterdam QT project, a QTc-interval >440 
ms was associated with a 2.3-times higher risk for SCD 
when compared with a QTc ≤440 ms (95% CI, 1.4–3.9) (20). 
Taken together, OSA seems capable of increasing, and 
CPAP seems capable of reducing, QTc in OSA patients with 
high baseline QTc, and thus decreasing risk for SCD.
Strengths and limitations
Many studies on repolarization changes are based on a one-
time analysis of standard 12-lead-ECGs and thus are prone 
to measurement-errors and in case of non-randomized 
studies, to type I error. In the current study, we used 24 
h-Holter-ECG data and calculated weighted means of 
all QTc-values, making measurement errors negligible. 
However, we analysed data from a previously published 
randomized trial, thus our interpretations must be regarded 
as hypothesis generating rather than fully robust. 
Conclusions
CPAP seems capable of improving an elevated QTc-interval, 
a biomarker for SCD, in patients with moderate-to-severe 
OSA. In selected patients, treatment with CPAP could, in 
addition to beneficial effects on systolic and diastolic blood 
pressure, possibly reduce the incidence of SCD. Future 
randomized trials could investigate the effect of CPAP on 
repolarization in moderate-to-severe OSA patients with 
prolonged QTc.
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